-
1.发明授权Benzothiazepine and benzothiazepine derivatives with ileal bile acid transport (IBAT) inhibotory activity for the treatment hyperlipidaemia 有权苯并硫氮嗪和苯并硫氮杂衍生物与回肠胆汁酸转运（IBAT）的抑制作用，用于治疗高脂血症公开(公告)号：US07132416B2
公开(公告)日：2006-11-07
申请号：US10488870
申请日：2002-09-05
申请人： Ingemar Starke , Mikael Ulf Johan Dahlstrom , David Blomberg , Suzanne Alenfalk , Tore Skjaret , Malin Lemurell
发明人： Ingemar Starke , Mikael Ulf Johan Dahlstrom , David Blomberg , Suzanne Alenfalk , Tore Skjaret , Malin Lemurell
IPC分类号： C07D281/02 , A61K38/05 , A61K38/06
CPC分类号： C07D417/12 , C07D285/36
摘要： The present invention relates to compounds of formula (I) wherein Rv, R1, R2, Rx, Ry, M, Rz, v, R3, R4, R5 and R6 are as defined within; pharmaceutically acceptable salts, solvates, solvates of such salts and prodrugs thereof and their use as ileal bile acid transport (IBAT) inhibitors for the treatment of hyperlipidaemia. Processes for their manufacture and pharmaceutical compositions containing them are also described.
摘要翻译： 本发明涉及式（I）的化合物，其中R 1，R 2，R 2，R x，X 2， R 1，R 2，R 3，R 4，R 4，R 4， 5＆lt; 6＆gt;和＆lt; 6＆gt;的定义如下： 药学上可接受的盐，溶剂合物，这些盐的溶剂合物和前药，以及它们作为回肠胆汁转运（IBAT）抑制剂用于治疗高脂血症的用途。 还描述了其制备方法和含有它们的药物组合物。
-
2.发明授权公开(公告)号：US07192947B2
公开(公告)日：2007-03-20
申请号：US10518010
申请日：2003-06-10
IPC分类号： A61P3/06 , A61K31/554 , C07D281/10
CPC分类号： C07K5/06078 , A61K38/00
摘要： The present invention relates to compounds of formula (I): (wherein variable groups are as defined within) pharmaceutically acceptable salts, solvates, solvates of such salts and prodrugs thereof and their use as ileal bile acid transport (IBAT) inhibitors for the treatment of hyperlipidaemia. Process for their manufacture and pharmaceutical compositions containing them are also described
摘要翻译： 本发明涉及式（I）的化合物：（其中可变基团如本文所定义）其药学上可接受的盐，溶剂合物，这些盐的溶剂合物和前药以及它们作为回肠胆汁转运（IBAT）抑制剂用于治疗 高脂血症 还描述了其制备方法和含有它们的药物组合物
-
3.发明申请Benzothiazepine and benzothiazepine derivatives with ileal bile acid transport (ibat) inhibitory activity for the treatment hyperlipidaemia 有权具有回肠胆汁酸运输（ibat）抑制活性的苯并硫氮嗪和苯并硫氮因衍生物用于治疗高脂血症公开(公告)号：US20050038009A1
公开(公告)日：2005-02-17
申请号：US10488870
申请日：2002-09-05
申请人： Ingemar Starke , Mikael Dahlstrom , David Blomberg , Suzanne Alenfalk , Tore Skjaret , Malin Lemurell
发明人： Ingemar Starke , Mikael Dahlstrom , David Blomberg , Suzanne Alenfalk , Tore Skjaret , Malin Lemurell
IPC分类号： A61K20060101 , A61K31/192 , A61K31/397 , A61K31/40 , A61K31/505 , A61K31/554 , A61K31/695 , A61K31/785 , A61P20060101 , A61P3/06 , A61P7/02 , A61P9/00 , A61P9/04 , A61P9/06 , A61P9/08 , A61P9/10 , A61P17/02 , A61P31/00 , A61P43/00 , C07D20060101 , C07D281/02 , C07D281/10 , C07D285/36 , C07D417/12 , C07F7/10 , C07K20060101 , C07D291/08
CPC分类号： C07D417/12 , C07D285/36
摘要： The present invention relates to compounds of formula (I) wherein Rv, R1, R2, Rx, Ry, M, Rz, v, R3, R4, R5 and R6 are as defined within; pharmaceutically acceptable salts, solvates, solvates of such salts and prodrugs thereof and their use as ileal bile acid transport (IBAT) inhibitors for the treatment of hyperlipidaemia. Processes for their manufacture and pharmaceutical compositions containing them are also described.
摘要翻译： 本发明涉及式（I）化合物，其中R 1，R 2，R 2，R x，R y，M，R z，v，R 3， R 4，R 5和R 6如上所定义; 药学上可接受的盐，溶剂合物，这些盐的溶剂合物和前药，以及它们作为回肠胆汁转运（IBAT）抑制剂用于治疗高脂血症的用途。 还描述了其制备方法和含有它们的药物组合物。
-
4.发明申请Peptides derivatives comprising thiazepine group for the treatment of hyperlipidermic conditions 有权含有硫氮杂基团的肽衍生物用于治疗高脂皮质病症公开(公告)号：US20050222120A1
公开(公告)日：2005-10-06
申请号：US10518010
申请日：2003-06-10
IPC分类号： A61K38/00 , A61P3/06 , A61P9/10 , C07K5/065 , A61K31/554 , C07D281/08
CPC分类号： C07K5/06078 , A61K38/00
摘要： The present invention relates to compounds of formula (I): (wherein variable groups are as defined within) pharmaceutically acceptable salts, solvates, solvates of such salts and prodrugs thereof and their use as ileal bile acid transport (IBAT) inhibitors for the treatment of hyperlipidaemia. Process for their manufacture and pharmaceutical compositions containing them are also described.
摘要翻译： 本发明涉及式（I）的化合物：（其中可变基团如本文所定义）其药学上可接受的盐，溶剂合物，这些盐的溶剂合物和前药以及它们作为回肠胆汁转运（IBAT）抑制剂用于治疗 高脂血症 还描述了其制备方法和含有它们的药物组合物。
-
5.发明授权Diphenylazetidinone derivatives for treating disorders of the lipid metabolism 失效用于治疗脂质代谢紊乱的二苯基氮杂环丁酮衍生物公开(公告)号：US07470678B2
公开(公告)日：2008-12-30
申请号：US10519897
申请日：2003-07-01
申请人： Ingemar Starke , Mikael Ulf Johan Dahlstrom , Ann-Margret Lindqvist , Mats Peter Nordberg , Tore Skjaret , Malin Anita Lemurell
发明人： Ingemar Starke , Mikael Ulf Johan Dahlstrom , Ann-Margret Lindqvist , Mats Peter Nordberg , Tore Skjaret , Malin Anita Lemurell
IPC分类号： C07D205/08 , A61K31/397 , A61P3/06 , A61P9/10 , A61P7/02
CPC分类号： C07D409/12 , C07D205/08
摘要： Compounds of formula (I): (wherein variable groups are as defined within) pharmaceutically acceptable salts, solvates, solvates of such salts and prodrugs thereof and their use as cholesterol absorption inhibitors for the treatment of hyperlipidaemia are described. Processes for their manufacture and pharmaceutical compositions containing them are also described
摘要翻译： 描述式（I）的化合物（其中可变基团如本文所定义）其药学上可接受的盐，溶剂合物，这些盐的溶剂合物和前药以及它们作为用于治疗高脂血症的胆固醇吸收抑制剂的用途。 还描述了其制备方法和含有它们的药物组合物
-
6.发明申请Novel 2-Azetidinone Derivatives And Their Use As Cholesterol Absorption Inhibitors For The Treatment Of Hyperlipidaemia 失效新型2-氮杂环丁酮衍生物及其用作治疗高脂血症的胆固醇吸收抑制剂公开(公告)号：US20100216759A1
公开(公告)日：2010-08-26
申请号：US11993033
申请日：2006-06-19
申请人： Susanne Alenfalk , Mikael Dahlstrom , Fana Hunegnaw , Staffan Karlsson , Malin Lemurell , Ann-Margret Lindqvist , Tore Skjaret , Ingemar Starke
发明人： Susanne Alenfalk , Mikael Dahlstrom , Fana Hunegnaw , Staffan Karlsson , Malin Lemurell , Ann-Margret Lindqvist , Tore Skjaret , Ingemar Starke
IPC分类号： A61K31/397 , C07D205/04 , A61P9/00
CPC分类号： C07D205/08 , C07K5/06026
摘要： Compounds of formula (I) (wherein variable groups are as defined within) pharmaceutically acceptable salts, solvates, solvates of such salts and prodrugs thereof and their use as cholesterol absorption inhibitors for the treatment of hyperlipidaemia are described. Processes for their manufacture and pharmaceutical compositions containing them are also described.
摘要翻译： 描述了式（I）化合物（其中可变基团如本文所定义）药学上可接受的盐，溶剂合物，这些盐的溶剂合物和前药，以及它们作为用于治疗高脂血症的胆固醇吸收抑制剂的用途。 还描述了其制备方法和含有它们的药物组合物。
-
7.发明申请Diphenylazetidinone derivatives possessing chloesterol absorption inhibitory activity 审中-公开具有氯黄酮吸收抑制活性的二苯基氮杂环丁酮衍生物公开(公告)号：US20070142304A1
公开(公告)日：2007-06-21
申请号：US10596725
申请日：2004-12-21
申请人： Susanne Alenfalk , Mikael Dahlstrom , Fana Hunegnaw , Staffan Karlsson , Malin Lemurell , Ann-Margret Lindqvist , Tore Skjaret , Ingemar Starke
发明人： Susanne Alenfalk , Mikael Dahlstrom , Fana Hunegnaw , Staffan Karlsson , Malin Lemurell , Ann-Margret Lindqvist , Tore Skjaret , Ingemar Starke
CPC分类号： C07D205/08
摘要： Compounds of formula (XV): [Chemical formula should be inserted here. Please see paper copy] (XV) (wherein variable groups are as defined within) pharmaceutically acceptable salts, solvates, solvates of such salts and prodrugs thereof and their use as cholesterol absorption inhibitors for the treatment of hyperlipidaemia are described. Processes for their manufacture and pharmaceutical compositions containing them are also described.
摘要翻译： 式（XV）化合物：[化学式应在此插入。 描述了可药用盐，溶剂合物，这些盐及其前药的溶剂化物及其作为治疗高脂血症的胆固醇吸收抑制剂的用途的文献（XV）（XV）（其中可变基团在其中定义）。 还描述了其制备方法和含有它们的药物组合物。
-
8.发明申请Diphenylazetidinone Derivatives Possessing Cholesterol Absorption Inhibitory Activity 失效具有胆固醇吸收抑制活性的二苯基氮杂环丁酮衍生物公开(公告)号：US20100099657A2
公开(公告)日：2010-04-22
申请号：US10596731
申请日：2006-11-16
申请人： Susanne Alenfalk , Mikael Dahlstrom , Fana Hunegnaw , Staffan Karlsson , Malin Lemurell , Ann-Margret Lindqvist , Tore Skjaret , Ingemar Starke
发明人： Susanne Alenfalk , Mikael Dahlstrom , Fana Hunegnaw , Staffan Karlsson , Malin Lemurell , Ann-Margret Lindqvist , Tore Skjaret , Ingemar Starke
IPC分类号： A61K31/397 , A61K31/4025 , A61K31/405 , A61P25/28 , A61P3/06 , A61P35/00 , A61P9/10 , C07D205/04 , C07D403/02
CPC分类号： C07D205/08 , A61K38/00 , C07K5/06026 , C07K5/06078
摘要： Compounds of formula (I) (wherein variable groups are as defined within) pharmaceutically acceptable salts, solvates, solvates of such salts and prodrugs thereof and their use as cholesterol absorption inhibitors for the treatment of hyperlipidaemia are described. Processes for their manufacture and pharmaceutical compositions containing them are also described.
摘要翻译： 描述了式（I）化合物（其中可变基团如本文所定义）药学上可接受的盐，溶剂合物，这些盐的溶剂合物和前药，以及它们作为用于治疗高脂血症的胆固醇吸收抑制剂的用途。 还描述了其制备方法和含有它们的药物组合物。
-
9.发明申请Diphenylazetidinone Derivatives Possessing Cholesterol Absorption Inhibitory Activity 失效具有胆固醇吸收抑制活性的二苯基氮杂环丁酮衍生物公开(公告)号：US20080064676A1
公开(公告)日：2008-03-13
申请号：US10596731
申请日：2004-12-21
申请人： Susanne Alenfalk , Mikael Dahlstrom , Fana Hunegnaw , Staffan Karlsson , Malin Lemurell , Ann-Margret Lindqvist , Tore Skjaret , Ingemar Starke
发明人： Susanne Alenfalk , Mikael Dahlstrom , Fana Hunegnaw , Staffan Karlsson , Malin Lemurell , Ann-Margret Lindqvist , Tore Skjaret , Ingemar Starke
IPC分类号： A61K31/397 , A61K31/4025 , A61K31/405 , A61P25/28 , A61P3/06 , A61P35/00 , A61P9/10 , C07D205/04 , C07D403/02
CPC分类号： C07D205/08 , A61K38/00 , C07K5/06026 , C07K5/06078
摘要： Compounds of formula (I) (wherein variable groups are as defined within) pharmaceutically acceptable salts, solvates, solvates of such salts and prodrugs thereof and their use as cholesterol absorption inhibitors for the treatment of hyperlipidaemia are described. Processes for their manufacture and pharmaceutical compositions containing them are also described.
摘要翻译： 描述了式（I）化合物（其中可变基团在其中定义）药学上可接受的盐，溶剂合物，这些盐的溶剂合物和前药，以及它们作为用于治疗高脂血症的胆固醇吸收抑制剂的用途。 还描述了其制备方法和含有它们的药物组合物。
-
10.发明授权2-azetidinone derivatives and their use as cholesterol absorption inhibitors for the treatment of hyperlipidaemia 失效2-氮杂环丁酮衍生物及其作为治疗高脂血症的胆固醇吸收抑制剂的用途公开(公告)号：US07863265B2
公开(公告)日：2011-01-04
申请号：US11993033
申请日：2006-06-19
申请人： Susanne Alenfalk , Mikael Dahlstrom , Fana Hunegnaw , Staffan Karlsson , Malin Lemurell , Ann-Margret Lindqvist , Tore Skjaret , Ingemar Starke
发明人： Susanne Alenfalk , Mikael Dahlstrom , Fana Hunegnaw , Staffan Karlsson , Malin Lemurell , Ann-Margret Lindqvist , Tore Skjaret , Ingemar Starke
IPC分类号： A61K31/397 , C07D205/08 , C07D413/12 , C07D319/06 , A61P3/06
CPC分类号： C07D205/08 , C07K5/06026
摘要： Compounds of formula (I) (wherein variable groups are as defined within) pharmaceutically acceptable salts, solvates, solvates of such salts and prodrugs thereof and their use as cholesterol absorption inhibitors for the treatment of hyperlipidaemia are described. Processes for their manufacture and pharmaceutical compositions containing them are also described.
摘要翻译： 描述了式（I）化合物（其中可变基团如本文所定义）药学上可接受的盐，溶剂合物，这些盐的溶剂合物和前药，以及它们作为用于治疗高脂血症的胆固醇吸收抑制剂的用途。 还描述了其制备方法和含有它们的药物组合物。
-
-
-
-
-
-
-
-
-
搜索结果
13 条记录 (耗时 0.039 秒)
